Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s): DHTRF

Healthcare Biotechnology

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.

TSX:DHT.UN - Post by User

Dri Healthcare Trust

<< Previous

Bullboard Posts

Next >>

(22)
•••

Comment by HermannHalleron Apr 22, 2025 3:42pm

60 Views

Post# 36547214

RE:RE:RE:RE:T3 Error Update

As you noted, mgmt get more shares in reorg if share price is low. So they have little incentive to boost the price right now (perhaps why they decided to hold on the NCIB?). Not fair to other shareholders of course.

Given that, would they announce the mgmt reorg before June 17, to avoid any boost in the unit price that might come from the FDA approval?

<< Previous

Bullboard Posts

Next >>

Market Open: Israel Strikes On Iran Dip Canada's Index Futures Down | Fri. June 13